TM7SF2 encodes a transmembrane protein that catalyzes the reduction of the C14-unsaturated bond of lanosterol as a critical step in cholesterol biosynthesis 1. The protein contains seven transmembrane domains and possesses 3beta-hydroxysterol Delta14-reductase activity 2. TM7SF2 expression is sterol-regulated, with upregulation occurring during sterol starvation through SREBP-2-mediated promoter activation 1. Beyond cholesterol synthesis, TM7SF2 plays tissue-specific roles in genome organization and function. In primary hepatocytes, TM7SF2 regulates radial positioning of cholesterol synthesis pathway genes (Cyp51, Msmo1) and influences metabolic outcomes including insulin sensitivity and Akt kinase activity 3. Regarding disease relevance, TM7SF2 has emerged as a significant factor in multiple pathologies. In colorectal cancer, elevated TM7SF2 expression correlates with advanced clinical stage and poor prognosis, with knockdown suppressing cell proliferation, migration, and invasion 4. Additionally, TM7SF2 expression is causally associated with gout susceptibility 5. In cancer progression, the METTL16/m6A/TM7SF2 axis promotes lipid reprogramming and colorectal cancer metastasis through IGF2BP1/IGF2BP2-dependent mRNA stabilization 6. Conversely, TM7SF2 inhibition promotes oligodendrocyte formation and remyelination through sterol substrate accumulation, suggesting therapeutic potential for demyelinating diseases 7.